MARINUS PHARMACEUTICALS Reports FY2022 Q4 Earnings Results on March 7 2023
March 18, 2023
Earnings Overview
Marinus Pharmaceuticals ($BER:0MV) released its fiscal year 2022 fourth quarter earnings results on March 7, 2023. Revenue for the quarter was USD -34.3 million, a decrease of 21.2% year-over-year. However, net income rose 371.1%, coming in at USD 7.2 million compared to the same period in the previous year.
Market Price
On Tuesday, March 7 2023, MARINUS PHARMACEUTICALS released their FY2022 Q4 earnings results. The company’s stock opened at €6.6 and closed at €6.7, representing a slight increase of 1.5% from the previous closing price of €6.6. This increase in the stock price was indicative of a healthy financial quarter for the company. The release of the financial results by MARINUS PHARMACEUTICALS was much anticipated by investors and analysts alike. The company has been performing strongly for the past few quarters and investors were expecting to see another strong performance in this quarter.
Thankfully, the stock market reacted positively to MARINUS PHARMACEUTICALS’ financial results, reflecting confidence in the company’s future prospects. Furthermore, the company also announced plans to invest in new research and development initiatives, which will likely bring more opportunities for growth in the near future. Overall, MARINUS PHARMACEUTICALS’ FY2022 Q4 earnings report is good news for investors, as it shows that the company is still performing well despite challenging market conditions. This is likely to contribute to further confidence in the stock and could lead to more gains in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Marinus Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 25.48 | -19.82 | -77.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Marinus Pharmaceuticals. More…
| Operations | Investing | Financing |
| -112.89 | 105.77 | 124.74 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Marinus Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 259.52 | 143.52 | 2.34 |
Key Ratios Snapshot
Some of the financial key ratios for Marinus Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -22.6% |
| FCF Margin | ROE | ROA |
| -450.0% | -3.6% | -1.4% |
Analysis
At GoodWhale, we provide investors with a comprehensive analysis of MARINUS PHARMACEUTICALS‘s fundamentals. Our rating shows that the company is a medium risk investment in terms of financial and business aspects. Furthermore, our analysis has detected two risk warnings in the cashflow statement and financial journal. To get more information on these warnings, register with us today to access our detailed reports. Our reports provide insights on a variety of factors, such as financial stability, key performance indicators, and more. With our help, you can make an informed decision about whether or not MARINUS PHARMACEUTICALS is the right choice for you. More…
Summary
Marinus Pharmaceuticals reported their fourth quarter earnings results for FY2022 on March 7th 2023 with a revenue of -34.3 million, a decrease of 21.2% year-over-year (YoY). Despite the decrease in revenue, the company posted a net income of 7.2 million, an increase of 371.1% YoY. This is a promising result for investors who want to gain exposure to the pharmaceutical industry.
Further analysis should be done to understand the drivers behind this increase in income, such as an increase in efficiency, cost-cutting measures, or higher demand for their products. Investors should also consider their current financials, competitors, and any potential risks, as well as their future prospects and growth opportunities.
